Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

Axcella Therapeutics announced that the US FDA has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.